RESULTS:
The study population included 39 patients and 28 controls. Bleeding score was $2 (ie, suggestive of a moderate bleeding diathesis) in 15 patients (38.5%) and $4 (ie, suggestive of a severe bleeding diathesis) in 7 (17.9%). Abnormal coagulation and/or platelet function tests were found in 14 patients with bleeding score $2 (93.3%) but also in 21 (87.5%) of those with bleeding score ,2. The prothrombin time and activated partial thromboplastin time were prolonged in 18 patients (46%) and partial deficiency of factor VII, alone or in combination with the deficiency of other vitamin K-dependent factors, was the most frequent coagulation abnormality. Moreover, platelet aggregation and secretion were reduced in 29 of 35 patients (82.9%, P , .01 for all aggregating agents).
CONCLUSIONS:
Nearly 40% of patients with the Noonan syndrome had a bleeding diathesis and .90% of them had platelet function and/or coagulation abnormalities. Results of these tests should be taken into account in the management of bleeding or invasive procedures in these patients. Pediatrics 2014;133:e1299-e1304 
METHODS Patients
Thirty-nine patients with Noonan syndrome regularly followed at the Pediatric Unit and 28 healthy individuals of similar age referred to the presurgery outpatient clinic with no history of bleeding were investigated. Inflammatory conditions were also excluded because they can raise some coagulation factors and thus affect coagulation tests. The history of bleeding was assessed in patients and controls using a validated bleeding score 15 : briefly a trained hematologist (AA or SMP) collected data on the severity of bleeding symptoms in the mucosal tracts (nasal, oral, gastrointestinal), organs (skin, uterus, brain), and joints. For each symptom, a score from -1 to 4 was assigned, and the total score (ie, the bleeding score) was calculated ( Table 1 ). The bleeding score was considered indicative of a mild bleeding diathesis when $2 and of a moderate/ severe bleeding diathesis when $4. 16 The questionnaire was administered to the study participants or their parents as appropriate, and clinical records were reviewed. Before venipuncture, the use of antiplatelet drugs in the previous week was carefully checked, and in such cases, blood sampling was postponed for at least 10 days to avoid interference with platelet function tests. Informed consent for the study was obtained from patients and control subjects or their parents, if patients were aged ,18 years. The study was approved by the hospital institutional review board.
Laboratory Methods
Blood was collected in Vacutainer tubes containing 3.8% of sodium citrate as anticoagulant using a 23/25-G needle after $8 hours fasting from an antecubital vein minimizing stasis. Complete blood count was performed in Vacutainer tubes anticoagulated with ethylenediaminetetraacetic acid. For coagulation tests, blood was centrifuged at 3800 3 g for 15 minutes to obtain platelet-free plasma for prothrombin time (PT) and aPTT testing (Instrument Laboratory, Milan, Italy). If either the PT or aPTT alone was prolonged, FVII or FVIII, FIX, FXI, and FXII levels were measured, respectively. If only PT was prolonged FVII was measured, and if only aPTT was prolonged FVIII, FIX, FXI and FXII were measured. Normal coagulation factor activity level is set by our laboratory at $70%, with the exception of FVIII, which is normal .50%. For platelet function tests blood, was centrifuged for 15 minutes at 190 3 g to obtain platelet-rich plasma.
The remaining blood was further centrifuged at 1100 3 g to obtain platelet-poor plasma. Platelet aggregation studies were performed on a Chrono-Log lumi aggregometer (Mascia Brunelli, Milan, Italy): 450 mL of plateletrich plasma were mixed with 50 mL of lucipherase and gently stirred at 1000 rpm at 37°C. 
RESULTS

Bleeding Symptoms
The general characteristics of the study population are represented in Table 2 .
Fifteen patients (38.5%) had a bleeding score $2, which was $4 in 7 of these patients (17.9%). Bleeding symptoms were generally mild, the most frequent being easy bruising and epistaxis in 46% of patients (Table 3) . Twenty patients had undergone 33 surgical interventions, 5 of which (2 cryptorchidism Table 4 shows the relationship between the bleeding score and coagulation and/or platelet function abnormalities, also in relation to surgical intervention. Overall, coagulation and/or platelet function abnormalities were found in 35 of 39 patients (89.7%, 6 coagulation, 17 platelet function, and 12 both abnormalities).
Coagulation Tests
In 21 patients, PTand aPTTwere normal, whereas in 18 patients and 4 controls (P = .008), 1 or both tests was prolonged (Table 5 ). All the patients with a prolonged PT and a normal aPTT had partial FVII deficiency, alone or in combination with other coagulation factor deficiencies. In 3 patients with FVII deficiency, the administration of a single sublingual vitamin K dose (5-10 mg) was followed by the normalization of both the PT and FVII. The aPTT was prolonged in 10 patients (3 of whom had also a prolonged PT) mainly due to FXII deficiency. Among controls, 1 had prolonged PT due to partial FVII deficiency, 2 had prolonged aPTT due to partial FXII deficiency, and 1 had both tests prolonged because of FX deficiency (38%). Fibrinogen activity was normal in all patients and controls.
Platelet Aggregation Tests
Platelet aggregation/secretion tests were performed in 35 patients and 28 controls. All had a normal platelet count (median 228 000 platelets/mL; range 132 000-350 000). Twenty-nine patients and 7 controls (P , .0001) had platelet aggregation or secretion to $1 aggregating agent lower than the fifth percentile of the values obtained in the control group (Table 5 ). The percentage of platelet aggregation was significantly lower in patients than controls with all the aggregating agents (P , .01 for all aggregating agents; Fig 1) . Platelet secretion was also significantly lower in patients than controls, but only after stimuli such as collagen and U46619 (P , .01) and not with ADP or TRAP as aggregating agents (Fig 2) . Overall, 35 patients and 11 controls (P , .0001) had coagulation or platelet function abnormalities, whereas 12 patients and no controls (P = .0001) had both (Table 5) .
DISCUSSION
In this case-control study, a cohort of patients with Noonan syndrome was extensively investigated to identify hemostatic abnormalities leading to a bleeding diathesis, which is a common feature of this syndrome. We found that bleeding symptoms, when analyzed through a validated questionnaire and a resulting bleeding score, were present in nearly half of the patients, being generally mild and mostly represented by cutaneous or mucosal bleeding. However, 5 patients reported excessive postsurgical bleeding, which required blood transfusion in a 2-year-old boy who underwent a pulmonary valve stenosis intervention and in a 5-year-old boy who developed a duodenal hematoma after endoscopic biopsy. Both patients had abnormal coagulation and/or platelet function tests.
In our patients, the prevalence of coagulation and/or platelet abnormalities was high not only in those with a bleeding diathesis but also in those without (93.7% vs 87.5%). In addition, bleeding episodes were not only related to surgical interventions (15.2%) but were also spontaneous in a relevant proportion of patients (31.6%). PT and/ or aPTT were prolonged in ∼50% of patients due to various coagulation factor deficiencies. The most frequent abnormality was deficiency of the vitamin K-dependent FVII, perhaps because of insufficient dietary intake or reduced intestinal adsorption of this vitamin. 1 The oral administration of vitamin K resulted in the normalization of both FVII levels and PT.
Coagulation factor deficiencies, found in 46% of patients, were always mild and thus unlikely to explain the increased risk of spontaneous bleeding. The latter was more likely associated with platelet function abnormalities and indeed were found in 83% of patients. The most severe platelet function abnormalities, low aggregation and secretion in response to collagen, were found in 34% and 43% of patients, respectively. It should be pointed out that platelet function tests were performed with concentrations of aggregating agents able to cause a strong and sustained platelet aggregation in normal adults. Patients with Noonan syndrome had reduced platelet aggregation with all the agonists tested, suggesting an association among Noonan syndrome, a platelet function defect, and the bleeding tendency of these patients.
Some of our findings deserve a critical discussion. The bleeding score was based on a validated questionnaire on patients with bleeding symptoms and was less frequently abnormal than hemostasis tests. There are two possible reasons for this discrepancy. First, the questionnaire is sensitive to abnormalities of primary hemostasis (ie, platelet function) but not to those of secondary hemostasis (ie, coagulation). Second, it was previously validated 15 in an adult population to discriminate patients to be studied for primary hemostasis defects. Although these can be considered as limitations of the study, it should be pointed out that children have had a limited exposure to bleeding risk situations because of their relatively short life, and therefore it is likely that even low bleeding scores are able to detect a significant bleeding diathesis. 18 In addition, our data are in agreement with those stemming from a cohort of 79 adults with a bleeding diathesis and 21 controls in which platelet function abnormalities were identified by laboratory methods in only 50% of those with a high bleeding score. 19 Finally, in a large cohort of adults investigated in our center for a suspected abnormality of primary hemostasis, no correlation between platelet function abnormalities and the bleeding score was observed. 20 
CONCLUSIONS
